Literature DB >> 6648853

Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure.

M R Law, F G Ward, M E Hodson, B E Heard.   

Abstract

In a group of 23 patients with histologically confirmed malignant mesothelioma of the pleura who could not recall exposure to asbestos dust, survival was significantly longer than in a group of 83 patients with known exposure. Asbestos bodies were found by a quantitative method significantly less frequently in the unexposed than in the exposed group. The longer survival of patients without known exposure could not be correlated with any significant difference in the histological cell types of the tumours from those of exposed patients. In the 83 patients with known exposure survival did not relate to duration of exposure. Consequently, although the tumours of patients unable to recall exposure may be caused by unrecognised environmental contamination with asbestos dust, the longer survival of these patients would suggest a different aetiology.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6648853      PMCID: PMC459649          DOI: 10.1136/thx.38.10.744

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

2.  Relationship between occupations and asbestos-fibre content of the lungs in patients with pleural mesothelioma, lung cancer, and other diseases.

Authors:  F Whitwell; J Scott; M Grimshaw
Journal:  Thorax       Date:  1977-08       Impact factor: 9.139

3.  Malignant mesothelial tumors - histologic type and asbestos exposure.

Authors:  D Magner; A D McDonald
Journal:  N Engl J Med       Date:  1972-09-14       Impact factor: 91.245

4.  Prevalence of asbestos bodies in a necropsy series in East London: association with disease, occupation, and domiciliary address.

Authors:  I Doniach; K V Swettenham; M K Hathorn
Journal:  Br J Ind Med       Date:  1975-02

5.  Mesothelioma risks in a naval dockyard.

Authors:  G Sheers; R M Coles
Journal:  Arch Environ Health       Date:  1980 Sep-Oct

6.  Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour.

Authors:  M R Law; M E Hodson; B E Heard
Journal:  Thorax       Date:  1982-11       Impact factor: 9.139

7.  Features of asbestos-exposed and unexposed mesothelioma.

Authors:  A Hirsch; P Brochard; H De Cremoux; L Erkan; P Sebastien; L Di Menza; J Bignon
Journal:  Am J Ind Med       Date:  1982       Impact factor: 2.214

8.  Thirty-two cases of mesothelioma in Victoria, Australia: a retrospective survey related to occupational asbestos exposure.

Authors:  J E Milne
Journal:  Br J Ind Med       Date:  1976-05

9.  The significance of asbestos exposure in the diagnosis of mesothelioma: a 28-year experience from a major urban hospital.

Authors:  F M Hasan; G Nash; H Kazemi
Journal:  Am Rev Respir Dis       Date:  1977-05
  9 in total
  4 in total

1.  Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.

Authors:  D H Yates; B Corrin; P N Stidolph; K Browne
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

2.  Malignant mesothelioma: attributable risk of asbestos exposure.

Authors:  R Spirtas; E F Heineman; L Bernstein; G W Beebe; R J Keehn; A Stark; B L Harlow; J Benichou
Journal:  Occup Environ Med       Date:  1994-12       Impact factor: 4.402

3.  Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.

Authors:  Marina Vivero; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2017-09-08       Impact factor: 7.842

Review 4.  Additive Synergism between Asbestos and Smoking in Lung Cancer Risk: A Systematic Review and Meta-Analysis.

Authors:  Yuwadee Ngamwong; Wimonchat Tangamornsuksan; Ornrat Lohitnavy; Nathorn Chaiyakunapruk; C Norman Scholfield; Brad Reisfeld; Manupat Lohitnavy
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.